Origin reports Phase IIb data for plasma-generated nitric oxide in chronic diabetic foot ulcers

In October, Origin Inc. (Princeton, N.J.) reported interim data from the Phase IIb GENESIS trial in patients with chronic diabetic foot ulcers showing that plasma-generated nitric oxide met the primary endpoint of safety. Additionally, the product led to a 95% average reduction in wound size at 12 weeks, with 71% of wounds achieving complete closure...